HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goto, S. Articles by Ishida, H. Search for Related Content PubMed PubMed Citation Articles by Goto, S. Articles by Ishida, H.

CLINICAL RESEARCH: GLYCOPROTEIN IIB/IIIA INHIBITION IN ACUTE MI

Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions

Shinya Goto, MD, FACC^*,*, Noriko Tamura, BS^* and Hideyuki Ishida, PhD

^* Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan
Department of Physiology, Division of Cardiology, Tokai University School of Medicine, Kanagawa, Japan

Manuscript received October 29, 2003; revised manuscript received January 16, 2004, accepted February 24, 2004.

^* Reprint requests and correspondence: Dr. Shinya Goto, Division of Cardiology, Department of Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1143, Japan.
sgoto3{at}mac.com

OBJECTIVES: We examined the lytic effects of anti-glycoprotein (GP) IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions.

BACKGROUND: Anti-GP IIb/IIIa agents may influence platelet thrombi already formed.

METHODS: Blood samples were anticoagulated either by the specific antithrombin Argatroban (100 µM) or by unfractionated heparin (0.1 U/ml). After platelet thrombi were formed on a collagen surface following 6-min perfusion of whole blood obtained from eight adult donors containing fluorescinated platelets at a wall shear rate of 1,500 s^–1, additional blood samples from the same donors either containing or not containing anti-GP IIb/IIIa agents (abciximab, eptifibatide, or tirofiban) were perfused on these thrombi. The three-dimensional structures of the platelet thrombi were continuously observed by laser confocal microscopy equipped with a piezo-electric motor control unit and recorded.

RESULTS: The platelet thrombi started to dissolve after perfusion of blood containing the anti-GP IIb/IIIa agents, whereas their growth resumed after subsequent perfusion of control blood. Only a single layer of platelets having heights of 3 ± 1 µm, 3 ± 2 µm, and 3 ± 1 µm, respectively, could be seen after 6-min perfusion of blood containing abciximab, eptifibatide, and tirofiban, whereas the initial height of the platelet thrombi of 8 ± 2 µm increased to 11 ± 4 µm after subsequent perfusion of control blood (n = 8). The volume of the platelet thrombi, which was 3,352 ± 1,045 µm³ before starting the second perfusion, was reduced to 778 ± 102 µm³, 812 ± 122 µm³, and 856 ± 144 µm³ after 6-min perfusion of blood containing abciximab, eptifibatide, and tirofiban, respectively.

CONCLUSIONS: We have shown in this study that anti-GP IIb/IIIa agents possess the ability to dissolve platelet thrombi.

Abbreviations and Acronyms   GP = glycoprotein   NIH = National Institutes of Health   VWF = von Willebrand factor

This article has been cited by other articles:

				D. J. Kereiakes, M. A. Turco, J. Breall, N. Z. Farhat, R. L. Feldman, B. McLaurin, J. J. Popma, L. Mauri, P. Zimetbaum, J. Massaro, et al. A Novel Filter-Based Distal Embolic Protection Device for Percutaneous Intervention of Saphenous Vein Graft Lesions: Results of the AMEthyst Randomized Controlled Trial J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 248 - 257. [Abstract] [Full Text] [PDF]

				Y. Izuhara, S. Takahashi, M. Nangaku, S. Takizawa, H. Ishida, K. Kurokawa, C. van Ypersele de Strihou, N. Hirayama, and T. Miyata Inhibition of Plasminogen Activator Inhibitor-1: Its Mechanism and Effectiveness on Coagulation and Fibrosis Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 672 - 677. [Abstract] [Full Text] [PDF]

				M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1517 - 1524. [Abstract] [Full Text] [PDF]

				O. Ben-Yehuda Upstream/Downstream: Glycoprotein IIb/IIIa in Non-ST-Segment Elevation Myocardial Infarction J. Am. Coll. Cardiol., February 7, 2006; 47(3): 538 - 540. [Full Text] [PDF]

				S. Goto, N. Tamura, H. Ishida, and Z. M. Ruggeri Dependence of Platelet Thrombus Stability on Sustained Glycoprotein IIb/IIIa Activation Through Adenosine 5'-Diphosphate Receptor Stimulation and Cyclic Calcium Signaling J. Am. Coll. Cardiol., January 3, 2006; 47(1): 155 - 162. [Abstract] [Full Text] [PDF]

				J. E. Freedman Molecular Regulation of Platelet-Dependent Thrombosis Circulation, October 25, 2005; 112(17): 2725 - 2734. [Abstract] [Full Text] [PDF]

				S. Goto Propagation of Arterial Thrombi: Local and Remote Contributory Factors Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2207 - 2208. [Full Text] [PDF]